Thalidomide induced neuropathy
Evidence-based neurology checklist on thalidomide induced neuropathy: Demographic features Peripheral neuropathy is the major dose-limiting toxicity for Thalidomide Neuropathy develops in 70% of cases after 12 months It is a dying back axonopathy Risk factors Clinical features Nerve conduction…
Demographic features
- Peripheral neuropathy is the major dose-limiting toxicity for Thalidomide
- Neuropathy develops in 70% of cases after 12 months
- It is a dying back axonopathy
Risk factors
Clinical features
Nerve conduction studies (NCS)
Treatment
References
- Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 2010; 95:311-319.
- Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002; 59:1872-1875.
- Johnson DC, Corthals SL, Walker BA, et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 2011; 29:797-804.
- Sonneveld P, Jongen JLM. Dealing with neuropathy in plasma-cell dyscrasias. Hematology Am Soc Hematol Educ Program 2010; 2010:423-430.
- Zara G, Ermani M, Rondinone R, Arienti S, Doria A. Thalidomide and sensory neurotoxicity: a neurophysiological study. JNNP 2008; 79:1258-1261.
